Swedish Orphan Biovitrum (STO: SOBI), the Nordic biotech company known as Sobi, has published a financial summary for the fourth quarter and 2018 as a whole that paints a picture of rapid growth.
Revenue at the company was 2.57 billion Swedish kronor ($280 million) for the fourth quarter, growing 37% on the same period of 2017, while the full-year sales figure was 9.14 billion kronor, a 40% jump.
Earnings before interest, tax and amortization (EBITA) for the quarter hit 916 million kronor, up 48% and beating analyst estimates of 831 million kronor.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze